DAX23.933 -0,4%ESt505.371 -0,1%Top 10 Crypto14,25 +1,3%Dow42.216 +0,3%Nas19.176 +0,4%Bitcoin93.355 +0,6%Euro1,1353 -0,2%Öl63,84 -0,5%Gold3.294 -0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 RENK RENK73 HENSOLDT HAG000 Tesla A1CX3T Lufthansa 823212 BYD A0M4W9 Siemens Energy ENER6Y Infineon 623100 Mercedes-Benz Group (ex Daimler) 710000 D-Wave Quantum A3DSV9 Apple 865985 thyssenkrupp 750000 Deutsche Telekom 555750 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Berufungsgericht hebt Zoll-Blockade auf: DAX schließt unter 24.000er-Marke - Rekord außer Reichweite -- US-Börsen letztlich fester -- NVIDIA über Erwartungen -- Vonovia, C3.ai, Salesforce im Fokus
Top News
Tesla-Aktie im Blick: Dieses Produkt nennt Elon Musk "größtes Produkt aller Zeiten" Tesla-Aktie im Blick: Dieses Produkt nennt Elon Musk "größtes Produkt aller Zeiten"
Apple-Aktie: Apple könnte in der EU weitere Sprachassistenten zulassen Apple-Aktie: Apple könnte in der EU weitere Sprachassistenten zulassen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

CureVac Aktie

Handeln
CureVac Aktien-Sparplan
4,07 EUR +0,10 EUR +2,47 %
STU
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.878,16 Mio. EUR

KGV4,36Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2P71U

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINNL0015436031

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCVAC

CureVac Aktien News

DatumMeistgelesen
BenzingaCureVac (CVAC) Stock Rises After Q1 Update, Oncology Pipeline Gains Traction
EQS GroupEQS-News: CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
EQS GroupEQS-News: CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
Wer­bungCureVac-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
EQS GroupEQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
EQS GroupEQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
EQS GroupEQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
EQS GroupEQS-News: CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
EQS GroupEQS-News: CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators
BenzingaWhy CureVac (CVAC) Shares Are Volatile
BenzingaWhy CureVac (CVAC) Stock Is Moving
BenzingaWhy CureVac (CVAC) Stock Is Rising
ZacksIs the Options Market Predicting a Spike in CureVac (CVAC) Stock?
EQS GroupEQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
EQS GroupEQS-News: CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
EQS GroupEQS-News: CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
EQS GroupEQS-News: CureVac to Present at the 12th International mRNA Health Conference
EQS GroupEQS-News: CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
EQS GroupEQS-News: CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
EQS GroupEQS-News: CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
EQS GroupEQS-News: CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
EQS GroupEQS-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
EQS GroupEQS-News: CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
EQS GroupEQS-News: CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
ZacksCureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?
ZacksCureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?
EQS GroupEQS-News: CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
ZacksGSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
BenzingaGSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Financial TimesGSK signs €1.4bn mRNA vaccine deal with troubled biotech CureVac
EQS GroupEQS-News: CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
EQS GroupEQS-News: GSK and CureVac to Restructure Collaboration into New Licensing Agreement
EQS GroupEQS-News: CureVac Announces Voting Results of General Meeting
EQS GroupEQS-News: CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
EQS GroupEQS-News: CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
EQS GroupEQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
EQS GroupEQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
EQS GroupEQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
EQS GroupEQS-News: CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
EQS GroupEQS-News: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
EQS GroupEQS-News: CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Wer­bung

CureVac News

CureVac News: auf dieser Seite finden Sie alle CureVac News und Nachrichten zur CureVac Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CureVac News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CureVac News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.